Invention:
This invention is the discovery of triazebutadienes that rapidly release aryl diazonium ions at neutral pH with a half-life of approximately one minute.
Background:
In 2015, the global protein therapeutics market grew to nearly $174.7 billion due to trends in targeted therapies that resulted in fewer side effects. Monoclonal antibodies and biologics are the largest portion of newer medications in development, leaving room for the development of novel pathways and techniques to fuel the creation of new therapies.
Applications:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic assay companies
- Research centers
- Academic laboratories
Advantages:
- Can be time-released by protecting triazebutadienes with stable, enzymatically releasable groups
Status: issued U.S. patent #10,954,195
